Johnson & Johnson ' s Nipocalimab Granted U.S. FDA Fast Track Designation to Reduce the Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) in Alloimmunized Pregnant Adults

SPRING HOUSE, Pa. March 26, 2024– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for nipocalimab to reduce the risk of FNAIT in alloimmunizeda pregnant adults...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials